Login
$MCRB
$1.50 +$0.10 (7.14%) Live

$MCRB 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)

26 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

05 Aug 2026 8-K: Results of Operations and Financial Condition

SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS

04 Aug 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

This STOCK ISSUANCE AGREEMENT (this “Agreement”) is made and entered into as of July 31, 2026 by and between Seres Therapeutics, Inc., a Delaware corporation (the “Company”), and BMR-SIDNEY RESEARCH CAMPUS LLC, a Delaware limited liabili...

08 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ...

08 Jul 2026 8-K: Regulation FD Disclosure; Other Events

Seres Company Overview July 2026 Seres Therapeutics, Inc. © 2026 Exhibit 99.2

05 Jun 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of May 1, 2026 (the “Effective Date”), by and between 101 CPD LLC, a Delaware limited liability company (“Landlord”), and SERES THERAPEUTICS, INC., a Delaware corporatio...

01 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

05 May 2026 8-K: Results of Operations and Financial Condition

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks

16 Mar 2026 8-K: Other Events

Seres Therapeutics, Inc. (the “Company”) announced today that the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”) has been scheduled for June 9, 2026. All holders of record of common stock outstanding as of the ...

12 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026

02 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

Seres Therapeutics, Inc. (the “Company”) is pleased to confirm its offer to continue to employ you as a regular, full-time employee on the following terms, effective March 2, 2026 (the “Effective Date”):

05 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for

03 Oct 2025 8-K: Other Events

On September 23, 2025, Seres Therapeutics, Inc. (the “Company”) announced actions to reduce operating costs in order to extend its cash runway to provide additional opportunities to advance its strategic priorities.

06 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological mali...

22 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

07 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transpl...

22 Apr 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Seres Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware,

14 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more

The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ...

13 Mar 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; C...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support